MeiraGTx posted a sharp drop in service revenue and a wider net loss in Q3 2025. The company continues to invest heavily in R&D, while entering into major strategic collaborations to strengthen its pipeline and manufacturing capabilities.

MeiraGTx posted $3.7M in service revenue for Q2 2025, significantly up from $0.3M YoY, while narrowing its net loss to $38.8M. The company ended the quarter with $32.2M in cash and cash equivalents and continues to advance multiple late-stage programs and regulatory filings.

MeiraGTx experienced a pivotal quarter with positive interactions with the FDA for its late-stage clinical programs, strengthening its balance sheet through a strategic collaboration with Hologen AI, and progressing towards potential BLA filings. The company reported a net loss of $39.981 million for the quarter.

MeiraGTx reported a net loss of $147.8 million for the full year 2024, with total revenue of $33.279 million. The company achieved significant clinical and regulatory milestones, including a strategic collaboration with Hologen AI and RMAT designation for AAV2-hAQP1.

MeiraGTx reported a net loss of $39.3 million for Q3 2024, with service revenue from related parties at $10.9 million. The company highlighted clinical advancements, including positive data from the AAV-GAD bridging study for Parkinson's disease and three Rare Pediatric Disease Designations from the FDA.